Study Reveals Age-Related Neutrophil Activity May Drive Pulmonary Fibrosis in HPS-1

A groundbreaking study has identified a potential mechanism behind the development of life-threatening pulmonary fibrosis in people with Hermansky-Pudlak Syndrome type 1 (HPS-1), offering new insights that could lead to better treatments for this rare condition.

According to research published in the Orphanet Journal of Rare Diseases, age-related changes in immune cell activity may play a crucial role in the progression of lung fibrosis, the leading cause of mortality in people with HPS-1.

Hermansky-Pudlak Syndrome type 1 is a rare genetic disorder characterized by oculocutaneous albinism (reduced pigmentation in the skin, hair, and eyes), bleeding tendencies due to platelet dysfunction, and pulmonary fibrosis. While the albinism is present from birth, the lung fibrosis typically develops between ages 30 and 40 — significantly earlier than idiopathic pulmonary fibrosis seen in the general population.

Immune Cell Activity and Age

The researchers examined differences in inflammatory markers and immune cell function between younger and older patients with HPS-1. Their findings reveal that patients over 40 years old showed significantly elevated levels of neutrophil extracellular traps (NETs) and neutrophil granule proteins compared to both younger patients and healthy controls.

Neutrophils are white blood cells that form part of the body's immune response. The study found that these cells behave differently as people with HPS-1 age, potentially creating an inflammatory environment that promotes scarring in the lungs.

Connecting Inflammation and Fibrosis

Particularly notable was the discovery that inflammatory cytokines (IL-8, IL-6) and fibrosis-related markers (MMP-7 and MMP-8) were markedly higher in older patients with HPS-1.

The researchers also identified elevated levels of anandamide (AEA), a circulating marker associated with pulmonary fibrosis in HPS-1. This marker positively correlated with neutrophil activity in older patients, suggesting a connection between these immune cells and the development of lung scarring.

This research provides valuable insights into why pulmonary fibrosis develops in people with HPS-1 as they age. Currently, there are no FDA-approved therapies specifically for HPS-related pulmonary fibrosis, making these findings particularly significant.

By identifying neutrophil activation as a potential driver of disease progression, this study opens new avenues for therapeutic interventions that might target these specific immune mechanisms, potentially slowing or preventing the deadly lung complications associated with this rare form of albinism.